BioAtla BCAB
OTC BCAB
$1.80 -0.01 (-0.55%)
At close: Nov 10, 2026 · 4:00 PM EST

BioAtla (BCAB) EBITDA Margin (2020 - 2026)

Updated

BioAtla (BCAB) recorded EBITDA Margin of 3.49% in Q2 2026.

Analysis

BioAtla (BCAB) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, BioAtla's EBITDA Margin came in at -375.65% as of Jun 30, 2026, up 153.94 percentage points year-over-year; for FY2025, it was -2946.60%, down 2282.80 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +3834.52 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -663.80% in FY2024 and -38044.00% in FY2021 (-31262.88 pp).
  • The Q2 2026 figure is the highest quarterly EBITDA Margin in data going back to Q1 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 BioAtla 2.99 Mn -15.95 Mn - 3.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.49%
Dec 31, 2025 -461.80%
Sep 30, 2024 -100.38%
Jun 30, 2024 -2,415.89%
Jun 30, 2021 -12,053.20%
Sep 30, 2020 -5,153.33%
Jun 30, 2020 -2,265.79%
Mar 31, 2020 -1,003.37%
API Access

BioAtla EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY